These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 23337303)

  • 21. Prevalence and risk factors for extended-spectrum β-lactamase producing antimicrobial-resistant
    Omar MH; Kilale AM; Rashid HK; Mwakapeje ER; Onoka IM; Gimbi AA
    Pan Afr Med J; 2024; 47():193. PubMed ID: 39119113
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical spectrum of urine cultures positive for ESBL-producing Escherichia coli in hospitalized patients and impact on antibiotic use.
    Lepeule R; Leflon-Guibout V; Vanjak D; Zahar JR; Lafaurie M; Besson C; Lefort A;
    Med Mal Infect; 2014 Dec; 44(11-12):530-4. PubMed ID: 25311839
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phenotypic confirmation of extended-spectrum B-lactamases (ESBL) in clinical isolates of Escherichia coli and Klebsiella pneumoniae at the San Juan Veterans Affairs Medical Center.
    Del Carmen Rodríguez M; Vera DE; Ramírez-Ronda CH; Saavedra S
    P R Health Sci J; 2004 Sep; 23(3):207-15. PubMed ID: 15631176
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk factors for increasing multidrug resistance among extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species.
    Hyle EP; Lipworth AD; Zaoutis TE; Nachamkin I; Fishman NO; Bilker WB; Mao X; Lautenbach E
    Clin Infect Dis; 2005 May; 40(9):1317-24. PubMed ID: 15825035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and Laboratory Profile of Urinary Tract Infections Associated with Extended Spectrum β-Lactamase Producing Escherichia coli and Klebsiella pneumoniae.
    Al Yousef SA; Younis S; Farrag E; Moussa HSh; Bayoumi FS; Ali AM
    Ann Clin Lab Sci; 2016 Jul; 46(4):393-400. PubMed ID: 27466299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk factors and clinical outcomes of extended spectrum beta-lactamase (ESBL)-producing Escherichia coli septicemia at Srinagarind University Hospital, Thailand.
    Anunnatsiri S; Towiwat P; Chaimanee P
    Southeast Asian J Trop Med Public Health; 2012 Sep; 43(5):1169-77. PubMed ID: 23431823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in spanish hospitals (GEIH-BLEE Project 2002)].
    Hernández JR; Pascual A; Cantón R; Martínez-Martínez L;
    Enferm Infecc Microbiol Clin; 2003 Feb; 21(2):77-82. PubMed ID: 12586030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Control of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a children's hospital by changing antimicrobial agent usage policy.
    Lee J; Pai H; Kim YK; Kim NH; Eun BW; Kang HJ; Park KH; Choi EH; Shin HY; Kim EC; Lee HJ; Ahn HS
    J Antimicrob Chemother; 2007 Sep; 60(3):629-37. PubMed ID: 17599919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan.
    Liu HY; Lin HC; Lin YC; Yu SH; Wu WH; Lee YJ
    J Microbiol Immunol Infect; 2011 Oct; 44(5):364-8. PubMed ID: 21524974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis.
    Rodríguez-Baño J; Picón E; Gijón P; Hernández JR; Ruíz M; Peña C; Almela M; Almirante B; Grill F; Colomina J; Giménez M; Oliver A; Horcajada JP; Navarro G; Coloma A; Pascual A;
    Clin Infect Dis; 2010 Jan; 50(1):40-8. PubMed ID: 19995215
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low frequency of antibiotic resistance among urine isolates of Escherichia coli in the community, despite a major hospital outbreak with Klebsiella pneumoniae producing CTX-M-15 in Uppsala County.
    Lindbäck H; Lindbäck J; Sylvan S; Melhus A
    Scand J Infect Dis; 2010 Apr; 42(4):243-8. PubMed ID: 20085420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro activity of fosfomycin and other antimicrobials against uropathogenic Escherichia coli and Klebsiella pneumoniae at a tertiary care center in Lebanon.
    Araj GF; Jaber FA
    J Med Liban; 2012; 60(3):142-7. PubMed ID: 23198454
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk factors for and outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in children.
    Zaoutis TE; Goyal M; Chu JH; Coffin SE; Bell LM; Nachamkin I; McGowan KL; Bilker WB; Lautenbach E
    Pediatrics; 2005 Apr; 115(4):942-9. PubMed ID: 15805368
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of non-carbapenem antibiotics for pediatric patients with first febrile urinary tract infection due to extended-spectrum beta-lactamase-producing Escherichia coli.
    Abe Y; Inan-Erdogan I; Fukuchi K; Wakabayashi H; Ogawa Y; Hibino S; Sakurai S; Matsuhashi K; Watanabe Y; Hashimoto K; Ugajin K; Itabashi K
    J Infect Chemother; 2017 Aug; 23(8):517-522. PubMed ID: 28528936
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidemiology of urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Ena J; Arjona F; Martínez-Peinado C; López-Perezagua Mdel M; Amador C
    Urology; 2006 Dec; 68(6):1169-74. PubMed ID: 17169640
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and economic outcomes associated with community-acquired intra-abdominal infections caused by extended spectrum beta-lactamase (ESBL) producing bacteria in China.
    Hu B; Ye H; Xu Y; Ni Y; Hu Y; Yu Y; Huang Z; Ma L
    Curr Med Res Opin; 2010 Jun; 26(6):1443-9. PubMed ID: 20394469
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
    Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of changes in CLSI and EUCAST breakpoints for susceptibility in bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli.
    Rodríguez-Baño J; Picón E; Navarro MD; López-Cerero L; Pascual A;
    Clin Microbiol Infect; 2012 Sep; 18(9):894-900. PubMed ID: 21985560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections.
    Pullukcu H; Tasbakan M; Sipahi OR; Yamazhan T; Aydemir S; Ulusoy S
    Int J Antimicrob Agents; 2007 Jan; 29(1):62-5. PubMed ID: 17189097
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Increasing prevalence of fosfomycin resistance in extended-spectrum-beta-lactamase-producing Escherichia coli urinary isolates (2005-2009-2011)].
    Rodríguez-Avial C; Rodríguez-Avial I; Hernández E; Picazo JJ
    Rev Esp Quimioter; 2013 Mar; 26(1):43-6. PubMed ID: 23546462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.